{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T10:54:35Z","timestamp":1791111275776,"version":"4.1.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2012,11,26]],"date-time":"2012-11-26T00:00:00Z","timestamp":1353888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2012,11,26]],"date-time":"2012-11-26T00:00:00Z","timestamp":1353888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1038\/bmt.2012.219","type":"journal-article","created":{"date-parts":[[2012,11,26]],"date-time":"2012-11-26T11:45:05Z","timestamp":1353930305000},"page":"777-781","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Plerixafor and G-CSF for autologous stem cell mobilization in patients with NHL, Hodgkin\u2019s lymphoma and multiple myeloma: results from the expanded access program"],"prefix":"10.1038","volume":"48","author":[{"given":"P","family":"Shaughnessy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Uberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Devine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R T","family":"Maziarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Vose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Micallef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Jacobsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"McCarty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Stiff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Artz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E D","family":"Ball","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Berryman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Dugan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Joyce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F J","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Johns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"McSweeney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,11,26]]},"reference":[{"key":"BFbmt2012219_CR1","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","volume":"333","author":"T Philip","year":"1995","unstructured":"Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy sensitive non-Hodgkin\u2019s lymphoma. N Engl J Med 1995; 333: 1540\u20131545.","journal-title":"N Engl J Med"},{"key":"BFbmt2012219_CR2","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","volume":"359","author":"N Schmitz","year":"2002","unstructured":"Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M et al. Aggressive conventional chemotherapy compared with high dose chemotherapy with autologous haemopoietic stem cell transplantation for relapsed chemosensitive Hodgkin\u2019s disease: a randomized trial. Lancet 2002; 359: 2065\u20132071.","journal-title":"Lancet"},{"key":"BFbmt2012219_CR3","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1056\/NEJM199607113350204","volume":"335","author":"M Attal","year":"1996","unstructured":"Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Fran\u00e7ais du My\u00e9lome. N Engl J Med 1996; 335: 91\u201397.","journal-title":"N Engl J Med"},{"key":"BFbmt2012219_CR4","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1080\/10428190903096701","volume":"50","author":"JM Vose","year":"2009","unstructured":"Vose JM, Ho AD, Coiffier B, Corradini P, Khouri I, Sureda A et al. Advances in mobilization for the optimization of autologous stem cell transplantation. Leuk Lymphoma 2009; 50: 1412\u20131421.","journal-title":"Leuk Lymphoma"},{"key":"BFbmt2012219_CR5","doi-asserted-by":"crossref","first-page":"3961","DOI":"10.1182\/blood.V86.10.3961.bloodjournal86103961","volume":"86","author":"CH Weaver","year":"1995","unstructured":"Weaver CH, Hazelton B, Birch R, Palmer P, Allen C, Schwartzberg L et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995; 86: 3961\u20133969.","journal-title":"Blood"},{"key":"BFbmt2012219_CR6","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1634\/stemcells.21-5-568","volume":"21","author":"R Seggewiss","year":"2003","unstructured":"Seggewiss R, Buss EC, Herrmann D, Goldschmidt H, Ho AD, Fruehauf S . Kinetics of peripheral blood stem cell mobilization following G-CSF supported chemotherapy. Stem Cells 2003; 21: 568\u2013574.","journal-title":"Stem Cells"},{"key":"BFbmt2012219_CR7","doi-asserted-by":"publisher","first-page":"4767","DOI":"10.1200\/JCO.2008.20.7209","volume":"27","author":"JF DiPersio","year":"2009","unstructured":"DiPersio JF, Micallef IN, Stiff PJ, Bolwell BJ, Maziarz RT, Jacobsen E et al. Phase III prospective randomized double-blind placebo controlled trial of plerixafor plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol 2009; 27: 4767\u20134773.","journal-title":"J Clin Oncol"},{"key":"BFbmt2012219_CR8","doi-asserted-by":"crossref","first-page":"5720","DOI":"10.1182\/blood-2008-08-174946","volume":"113","author":"JF DiPersio","year":"2009","unstructured":"DiPersio JF, Standtmauer EA, Nademanee A, Micallef IN, Stiff PJ, Kaufman JL et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009; 113: 5720\u20135726.","journal-title":"Blood"},{"key":"BFbmt2012219_CR9","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1038\/bmt.2010.236","volume":"46","author":"S Sinha","year":"2011","unstructured":"Sinha S, Gastineau D, Micallef I, Hogan W, Ansell S, Buadi F et al. Predicting PBSC harvest failure using circulating CD34 levels: developing target-based cutoff points for early intervention. Bone Marrow Transplant 2011; 46: 943\u2013949.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2012219_CR10","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/bmt.2011.133","volume":"47","author":"S Abhyankar","year":"2012","unstructured":"Abhyankar S, Dejarnette S, Aljitawi O, Ganguly S, Merkel D, McGuirk J . A risk-based approach to optimize autologous hematopoietic stem cell (HSC) collection with the use of plerixafor. Bone Marrow Transplant 2012; 47: 483\u2013487.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2012219_CR11","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.bbmt.2010.08.018","volume":"17","author":"P Shaughnessy","year":"2011","unstructured":"Shaughnessy P, Islas-Ohlmayer M, Murphy J, Hougham M, MacPherson J, Winkler K et al. Cost and clinical analysis of autologous hematopoietic stem cell mobilization with G-CSF and plerixafor compared to G-CSF and cyclophosphamide. Biol Blood Marrow Transplant 2011; 17: 729\u2013736.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2012219_CR12","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/bmt.2009.119","volume":"45","author":"MJ Dugan","year":"2010","unstructured":"Dugan MJ, Maziarz RT, Bensinger WI, Nademanee A, Liesveld J, Badel K et al. Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma, non-Hodgkin\u2019s lymphoma undergoing stem cell mobilization. Bone Marrow Transplant 2010; 45: 39\u201347.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2012219_CR13","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1038\/bmt.2011.216","volume":"47","author":"K Hubel","year":"2012","unstructured":"Hubel K, Fresen MM, Apperley JF, Basak GW, Douglas KW, Gabriel IH et al. European data on stem cell mobilization with plerixafor in non-Hodgkin\u2019s lymphoma, Hodgkin\u2019s lymphoma, and multiple myeloma patients. A subgroup analysis of the European Consortium of stem cell mobilization. Bone Marrow Transplant 2012; 47: 1046\u20131050.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2012219_CR14","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/bmt.2010.78","volume":"46","author":"LJ Costa","year":"2011","unstructured":"Costa LJ, Alexander ET, Hogan KR, Shaub C, Fouts TV, Suart RK . Development and validation of a decision making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization. Bone Marrow Transplant 2011; 46: 64\u201369.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2012219_CR15","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1038\/bmt.2012.74","volume":"47","author":"AI Chen","year":"2012","unstructured":"Chen AI, Bains T, Murray S, Knight R, Shoop K, Bubalo J et al. Clinical experience with a simple algorithm for plerixafor utilization in autologous stem cell mobilization. Bone Marrow Transplant 2012; 47: 1526\u20131529.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2012219_CR16","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1038\/bmt.2011.217","volume":"47","author":"ME Horowitz","year":"2012","unstructured":"Horowitz ME, Chute JP, Gasparetto C, Long GD, McDonald C, Morris A et al. Preemptive dosing of plerixafor given to poor stem cell mobilizers on day 5 of G-CSF administration. Bone Marrow Transplant 2012; 47: 1051\u20131055.","journal-title":"Bone Marrow Transplant"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bmt2012219.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2012219","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2012219.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T15:17:49Z","timestamp":1648048669000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bmt2012219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11,26]]},"references-count":16,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["BFbmt2012219"],"URL":"https:\/\/doi.org\/10.1038\/bmt.2012.219","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11,26]]},"assertion":[{"value":"13 August 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2012","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2012","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2012","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was sponsored by Sanofi Oncology (previously Genzyme Corporation). PS, RTM, JMC, SD, MD and PMS received honoraria and research funding from Genzyme. IM, JV and PS received research funding from Sanofi\/Genzyme. FJH is a former Genzyme employee and is now an employee of Zyngenia, Inc. DJ is an employee of Sanofi Oncology (formerly Genzyme). All the other author declare no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}